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Abstract
Temporary cART during primary HIV-infection (PHI) did not select for drug resistance mutations after treatment interruption
and did not affect the subsequent virological response to long-term cART. Our data demonstrate that fear of drug resistance
development is not a valid argument to refrain from temporary early treatment during PHI.
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Introduction
In the Primo-SHM trial, a multicenter randomized trial
comparing no treatment with 24- or 60-weeks of combination
antiretroviral therapy (cART) during primary HIV-infection
(PHI), we recently demonstrated that temporary early cART
lowered the viral setpoint and deferred the need for reinitiation of
cART during chronic HIV-infection [1]. Two other randomized
studies also observed a modest delay in disease progression after a
short course of cART in PHI [2,3]. However, an important
concern of temporary early cART, and of structured treatment
interruptions (TI) in general, is the risk of developing drug
resistance mutations after TI, especially in the case of NNRTI-
based regimens, which compromise future treatment options.
The aim of this study was to assess the effect of temporary
cART during PHI on the subsequent virologic response to long-
term cART, in patients who previously participated in the Primo-
SHM trial. To this end, we compared the viral decay and the time
to viral (re)suppression between the early treated patients who
reinitiated cART and the patients in whom treatment was
deferred until conventional criteria to start long-term cART had
been reached.
Methods
Between May 2003 and March 2010 168 patients with
laboratory evidence of PHI were randomized in the Primo-
SHM trial to receive no treatment (naive patients, n = 36) or 24 or
60 weeks of early cART (early treated patients, n = 132) [1]. PHI
was defined as a negative or indeterminate Western blot combined
with a detectable plasma viral load (pVL), or, in case of a positive
Western blot, a negative HIV-screening test result #180 days.
Early cART consisted of a quadruple triple-class regimen
containing two NRTIs (zidovudine/lamivudine 300/150 mg
bid), an NNRTI (efavirenz 600 mg qd) and a boosted PI
(lopinavir/ritonavir capsules 533/133 mg bid). The latter was
discontinued when the pVL had dropped ,50 copies/ml. After
January 2008 zidovudine/lamivudine was replaced by tenofovir/
emtricitabine (245/200 mg qd) and lopinavir/ritonavir tablets
(600/150 mg bid) replaced the capsules. Changes to this regimen
were allowed in case of transmitted drug resistance or if one of the
drugs was not tolerated. The study protocol required patients to
reach a pVL ,50 copies/ml before interrupting therapy as
scheduled. Long-term cART was (re)started in case of two
consecutive CD4 cell counts below 350 cells/mm3, severe
constitutional symptoms, the occurrence of an AIDS defining
event, or if the patient preferred on (re)initiating cART. Follow-up
visits after (re)start of cART were scheduled according to standard
treatment guidelines, i.e. after four weeks of treatment and every
three months thereafter. This study was approved by the Medical
Ethics Committee of the Academic Medical Hospital in Am-
sterdam, the Netherlands, and written informed consent was
obtained from all participants.
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In the current study, we included the 94 out of 168 participants
(56%) who had started or restarted long-term cART by September
2011 and who had at least one pVL measurement after
(re)initiation of cART. (Re)Start regimens were at the discretion
of the treating physician. Resistance testing was performed at
diagnosis of PHI. To investigate possible acquired resistance
during or after stopping of early cART, we performed additional
resistance testing of the reverse transcriptase gene retrospectively
in the first stored plasma sample obtained within one year after TI
with a pVL above 3.0 log10 c/ml. Data of the 24- and 60-weeks
early treated patients were combined in all analyses because the
viral decay was not significantly different between the two groups
(data not shown).
Sociodemographic characteristics and laboratory data at
(re)start of long-term cART were compared between the naive
and early treated patients using chi-square, Fisher’s exact and
Kruskal-Wallis tests where appropriate. Viral decay after start/
restart of cART in naive/early treated patients was analysed using
linear mixed models incorporating repeated measurements, which
showed a tri-phasic pattern with distinct slopes from week zero to
four, week four to eight and from week eight onwards. For this
analysis patients were censored once they reached a pVL ,50 c/
ml. A similar analysis was done for the early treated group,
comparing viral decay during early initial cART with the decay
after subsequent restart of cART. Time to viral (re)suppression,
defined as a pVL ,50 c/ml, was compared between the two
groups using Kaplan-Meier plots and multivariable Cox regression
analysis. The proportion of patients having an undetectable viral
load (,50 c/mL) and the mean (SD) CD4+ T cell count in the two
groups were plotted and compared at 24-week intervals for 144
weeks after the (re-)start of cART. All analyses ignored modifica-
tions of treatment regimens, but censored patients at the moment
of interruption of cART for more than two weeks. Data were
analyzed using SAS version 9.2 (SAS institute, USA).
Results
Of the 36 naive and 132 early treated participants in the Primo-
SHM trial, 31 (86%) and 63 (48%) had (re)initiated long-term
cART by September 2011, respectively, and were included in this
study. At the time of diagnosis of PHI (so before any treatment was
started) the pVL and CD4 count data of the naı¨ve and early
treated patients were 5.14 (SD 0.90) versus 5.34 (0.73) log10 c/ml
(P= 0.24) and 446 (SD 164) versus 481 (236) cells/mm3 (P= 0.46),
respectively. Additionally, the naı¨ve patients had less transmitted
drug resistance mutations as compared to the early treated patients
at the moment of PHI-diagnosis (0 versus 8 (14%); P= 0.048). 5/8
early treated patients carried a M41L mutation, 2 patients a M46I
mutation of whom one also had a T215S mutation and one
carried a K103N mutation. In 52/63 early treated patients all
antiretroviral drugs had been stopped simultaneously at TI: at that
moment 31/63 (49%) were receiving dual-class NNRTI-based
therapy, 15/63 (24%) dual-class boosted PI-based therapy, and 6/
63 (10%) triple-class therapy. In the remaining 11/63 patients
(17%) a staggered TI method was used, in which the NNRTI was
stopped prior to the NRTI-backbone. Six early treated patients
(6%) did not have a pVL ,50 c/ml at TI (range 58–1882 copies/
ml). The median time between TI and restart of long-term cART
was 1.9 (IQR 0.9–3.1) years.
89/94 (re)starting participants (95%) were men. Mean age and
CD4 count at (re)start of long-term cART were 44 (SD 9) years
and 290 (110) cells/mm3, respectively, and were not significantly
different between the naive and early treated patients. The naive
patients had a higher mean pVL at (re)start (5.0 (SD 0.7) versus 4.7
(0.7) log10 c/ml; P= 0.07). Naive patients initiated long-term
cART more often with an NNRTI-containing regimen than early
treated patients (24 (77%) versus 37 (59%); P= 0.10). Four naive
(13%) and 23 early treated patients (37%) (re)started long-term
cART with a boosted PI (P= 0.03), and three (10%) versus three
(5%) patients, respectively, (re)initiated with triple-class therapy
(P= 0.40).
Drug resistance testing was performed after TI in 56/63 (89%)
early treated participants. None of these patients had developed a
novel (acquired) drug resistance mutation. Of the remaining seven
patients, one harboured a 103N mutation, which was already
present at diagnosis of PHI (this patient had started with a
quadruple NNRTI-based regimen before resistance testing results
were known, once results were available the regimen was adapted),
and for six patients no stored samples were available or the first
available stored sample was older than one year. The median
Table 1. Patient characteristics at (re)initiation of long-term cART.
Total (N=94)
No treatment during
PHI (N=31)
Early cART during PHI
(N=63) P-value
Age (years), mean (SD) 44 (9) 44 (10) 43 (8) 0.9
Men 89 (95) 31 (100) 58 (92) 0.2
MSM 78 (83) 26 (84) 52 (83) 0.9
Born in the Netherlands 84 (89) 28 (90) 56 (89) 1.0
History of CDC C-event 11 (12) 2 (7) 9 (14) 0.3
CD4 count (cells/mm3), mean (SD) 290 (110) 273 (133) 299 (96) 0.3
Plasma HIV-1 RNA (log10 copies/ml), mean (SD) 4.8 (0.7) 5.0 (0.7) 4.7 (0.7) 0.07
Subtype B virus 75 (88)` 25 (89)` 50 (88)` 1.0
Initiation of cART during chronic HIV-infection
- triple-class therapy 6 (6) 3 (10) 3 (5) 0.4
- dual-class NNRTI 61 (65) 24 (77) 37 (59) 0.1
- dual-class PI 27 (29) 4 (13) 23 (37) 0.03
Data are n (%) unless indicated otherwise. MSM, men who have sex with men; PHI, primary HIV infection.
`9 missing patients: 3 in the non-early treated and 6 in the early treated group.
doi:10.1371/journal.pone.0089639.t001
Viral Resuppression after Early cART
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interval between TI and the timepoint of resistance testing was 5.0
(IQR 4.0–8.0) weeks. In 3/56 patients the time point of resistance
testing was .12 weeks after TI. Other patient characteristics
(transmission route, ethnicity, history of CDC-events, virus
subtype) were comparable between the two groups. One early
treated patient was lost-to-follow-up after restart of long-term
cART and he was censored at this visit. Patient characteristics are
summarized in Table 1.
All naive and early treated patients achieved viral (re)suppres-
sion. The mean number of pVL measurements after (re)start of
cART, upto and including the first undetectable pVL, was 2.3 (SD
1.2) in the naive and 2.3 (1.5) in the early treated patients,
respectively (P= 0.87). The mean interval between pVL measure-
ments was not significantly different for the two groups (53 (SD 23)
vs. 50 (20) days, respectively, P= 0.54). Viral decay after treatment
(re)initiation was similar between the naive and early treated
patients: during the first four weeks the pVL decreased with 0.62
and 0.58 log10 copies/ml/week respectively (P= 0.32), from week
four to eight with 0.087 and 0.13 log10 copies/ml/week (P= 0.37),
and from eight weeks onward with 0.043 and 0.027 log10 copies/
ml/week (P= 0.23) (Figure 1). Adjusting the viral decay for the
difference in pVL at (re)start of long-term cART also showed no
significant differences between the two groups (data not shown).
The median time to viral (re)suppression in naive and early treated
patients was 16.4 (IQR 9.6–20.6) and 16.6 (8.7–21.0) weeks,
respectively (log-rank, P= 0.72). Figure 2 demonstrates that three
years after (re)initiation of long-term cART the proportion of
patients having an undetectable pVL was not significantly different
between the naive and early treated patients. In addition, the CD4
count recovery after treatment (re)initiation showed no differences
over time between the two groups (Figure 3).
In the Cox analysis early treatment during PHI as compared to
no treatment was not associated with time to viral resuppression
(HR 0.81 (95% CI 0.27–2.39); P= 0.70). As expected, a higher
vireamia at (re)start of long-term cART was predictive for a longer
time to viral suppression (HR 0.37 per 1 log10 copies/ml increase
(95% CI 0.25–0.56); P,0.001). Other parameters, including
reinitiating with an NNRTI-based regimen or with triple-class
therapy, were not associated with time to viral (re)suppression
(data not shown).
In the early treated group, the median time to viral
(re)suppression (Kaplan-Meier estimate) was longer in the early
treatment phase compared to the phase of long-term cART: 21.7
(IQR 12.0–24.7) and 16.6 (8.7–21.0) weeks (log-rank, P= 0.043),
respectively. This difference in time to first undetectable viral load
measurement appeared to be primarily driven by the higher viral
load at the time of start of early cART compared to the viral load
at the restart of cART in the phase of long-term cART. Therefore,
we additionally constructed mixed linear regression models
comparing viral decay during the early treatment episode and
subsequent restart of long-term cART (Figure 4). During the first
four weeks the pVL decreased with 0.52 and 0.57 log10 copies/
ml/week, respectively (P= 0.16), from week four to eight with 0.13
and 0.14 log10 copies/ml/week (P= 0.70), and from eight weeks
onward with 0.048 and 0.021 log10 copies/ml/week (P= 0.003).
Figure 1. Viral decay after treatment (re)initiation of long-term cART in naive and early treated patients.
doi:10.1371/journal.pone.0089639.g001
Figure 2. Proportion of patients with an undetectable pVL after
(re)initiation of long-term cART over a period of 144 weeks in
naive and early treated patients.
doi:10.1371/journal.pone.0089639.g002
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Discussion
Temporary cART during PHI did not select for clinically
relevant drug resistance mutations and was associated with a
durable and persisting virologic response after subsequent
reinitiation of long-term cART. Our data thereby support the
use of early treatment during PHI. Of note, the slower decline of
the pVL from 8 weeks onward in the second treatment period of
the early treated patients is probably an artefact of the model,
because patients had a lower baseline pVL at restart than during
early treatment and their pVL was usually already undetectable by
week 8.
We were not able to perform resistance testing after TI in 7/63
(11%) of the early treated patients. We therefore cannot exclude
with certainty that there might have been selection of drug
resistance after TI in these patients. This is in particular relevant
for patients who interrupted an NNRTI-based regimen, because
of the long half-life of NNRTIs. However, in all seven patients,
irrespective of the regimen, the pVL was resuppressed upon
restart, which virtually excludes clinically important mutations.
The early treated patients reinitiated long-term cART more often
with a boosted PI than naive patients. Many early treated patients
preferred not to restart an NNRTI because of side-effects they had
experienced previously during the early cART period, and
therefore favoured a PI-containing regimen.
Our study is supported by another study in which 37 PHI-
patients were treated with temporary early cART and no drug
resistance was observed after TI [4]. However, in this study the
NNRTI was stopped 96 h before the NRTI-backbone. Because
NNRTIs have a slower metabolism and a low genetic barrier to
resistance, simultaneous TI of an NNRTI-containing regimen
may result in a period of NNRTI-monotherapy, which may select
for drug resistance mutations [5]. NNRTI-drug resistance
mutations that were selected after intrapartum exposure to
single-dose nevirapine in HIV-infected women have been associ-
ated with decreased virologic response after subsequent treatment
with an NNRTI-containing regimen [6,7]. Noteworthy, the pVL
in these women exposed to single-dose nevirapine was much
higher than the pVL in a controlled TI-setting in which patients
have an undetectable pVL at TI. In the SMART trial [8],
NNRTI-drug resistance mutations were more common in case of
simultaneous TI than in case of a staggered or a switched
interruption, in which the NNRTI is replaced by a boosted PI [9].
However, in SMART most drug combinations included a
zidovudine/lamivudine-backbone in combination with an NNRTI
[8], whereas in our trial half of the patients were using a tenofovir-
containing regimen, which has a longer half-life [10], and together
with an NNRTI forms a more balanced regimen that is less prone
to development of drug resistance when treatment is discontinued
simultaneously. To date, there is no clear consensus how to stop
cART regimens [11]. In our study we found no indication for
selection of drug resistance mutations after interrupting all drugs
simultaneously once an undetectable pVL had been reached.
In conclusion, temporary cART during PHI was not associated
with a reduced virologic response after subsequent reinitiation of
long-term cART. Concerns for developing drug resistance
mutations after TI have not been substantiated. Therefore, fear
of drug resistance development is not a valid argument to refrain
from early treatment during PHI: even if patients interrupt early
treatment, they still have a good and durable response after
subsequent reinitiation of cART. A question is whether early
Figure 3. CD4 count recovery after treatment (re)initiation of
long-term cART in naive and early treated patients.
doi:10.1371/journal.pone.0089639.g003
Figure 4. Viral decay after treatment initiation of early cART and subsequent long-term cART in the early treated patients.
doi:10.1371/journal.pone.0089639.g004
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cART should be interrupted at all, butin our experience some
patients prefer to interrupt treatment after a period of early
treatment. In brief, this study contributes to the increasing data
supporting (temporary) early cART during PHI.
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